Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ionis Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was MXN3,127 Mil.
Ionis Pharmaceuticals's quarterly Ending Cash Position
increased
from Sep. 2025 (MXN6,207 Mil) to Dec. 2025 (MXN6,703 Mil) but then
declined
from Dec. 2025 (MXN6,703 Mil) to Mar. 2026 (MXN3,127 Mil).
Ionis Pharmaceuticals's annual Ending Cash Position
declined
from Dec. 2023 (MXN6,777 Mil) to Dec. 2024 (MXN5,049 Mil) but then
increased
from Dec. 2024 (MXN5,049 Mil) to Dec. 2025 (MXN6,703 Mil).
Ionis Pharmaceuticals Ending Cash Position Related Terms
Ionis Pharmaceuticals Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Ionis Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of MXN3,127 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Ending Cash Position of MXN3,127 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Ending Cash Position too high?
Ionis Pharmaceuticals' current Ending Cash Position is MXN3,127 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Ending Cash Position compare to EXEL and BBIO?
Ionis Pharmaceuticals' Ending Cash Position of MXN3,127 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Ending Cash Position is MXN3,127 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Ending Cash Position of MXN3,127 Mil. The stock's GF Value™ is MXN1,099.57, compared to a current price of MXN1,150.00 — trading 4.6% above its estimated fair value. The current Ending Cash Position is MXN3,127 Mil. Ionis Pharmaceuticals' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Ending Cash Position is MXN3,127 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,150.00 is trading 4.6% above its estimated GF Value™ of MXN1,099.57.
Key valuation signals for MEX:IONS:
Ending Cash Position: MXN3,127 Mil
GF Value™: MXN1,099.57 vs. price of MXN1,150.00 (4.6% above fair value)
No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
71GF Score
Get the complete analysis for MEX:IONS
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IONS has been successfully added to your 
